Viridian Shares New 52-Week Phase III Trial Data for Active TED
New THRIVE trial data highlight long-term proptosis response with veligrotug in thyroid eye disease patients. Fresh long-term data is showing…
From Variants to Function: Advanced Research in Genetic Interpretation at ARVO 2025
Nifty new approaches to genetic variants on display at ARVO 2025 are accelerating understanding of underlying disease mechanisms in eye…
latest posts